(19)
(11) EP 2 016 182 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
02.09.2015 Bulletin 2015/36

(45) Mention of the grant of the patent:
08.07.2015 Bulletin 2015/28

(21) Application number: 07732664.3

(22) Date of filing: 04.05.2007
(51) International Patent Classification (IPC): 
C12N 15/869(2006.01)
(86) International application number:
PCT/GB2007/001631
(87) International publication number:
WO 2007/132169 (22.11.2007 Gazette 2007/47)

(54)

MUTANT HSV, MATERIALS AND METHODS FOR GENERATION OF MUTANT HSV

MUTANTES HSV, MATERIALIEN UND VERFAHREN ZUR ERZEUGUNG DES MUTANTEN HSV

VIRUS HERPÈS SIMPLEX MUTANT ET MATÉRIAUX ET PROCÉDÉS PERMETTANT DE LE GÉNÉRER

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

(30) Priority: 11.05.2006 GB 0609383
23.10.2006 GB 0621051

(43) Date of publication of application:
21.01.2009 Bulletin 2009/04

(73) Proprietor: Virttu Biologics Limited
Winsford Cheshire CW7 3QN (GB)

(72) Inventor:
  • CONNER, Joe
    Glasgow, Strathclyde G51 4WF (GB)

(74) Representative: Clegg, Richard Ian et al
Mewburn Ellis LLP
City Tower 40 Basinghall Street London EC2V 5DE
City Tower 40 Basinghall Street London EC2V 5DE (GB)


(56) References cited: : 
   
  • GAGE P J ET AL: "A CELL-FREE RECOMBINATION SYSTEM FOR SITE-SPECIFIC INTEGRATION OF MULTIGENIC SHUTTLE PLASMIDS INTO THE HERPES SIMPLEX VIRUS TYPE 1 GENOME" JOURNAL OF VIROLOGY, NEW YORK, US, US, vol. 66, no. 9, 1 September 1992 (1992-09-01), pages 5509-5515, XP000568386 ISSN: 0022-538X
  • TERADA K ET AL: "Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models" GENE THERAPY, vol. 13, no. 8, April 2006 (2006-04), pages 705-714, XP002448244 ISSN: 0969-7128
  • KRISKY D M ET AL: "Rapid method for construction of recombinant HSV gene transfer vectors" GENE THERAPY, MACMILLAN PRESS LTD., BASINGSTOKE, GB, vol. 10, no. 4, October 1997 (1997-10), pages 1120-1125, XP002079298 ISSN: 0969-7128
  • LANDY A: "DYNAMIC, STRUCTURAL, AND REGULATORY ASPECTS OF LAMBDA SITE-SPECIFIC RECOMBINATION" ANNUAL REVIEW OF BIOCHEMISTRY, PALTO ALTO, CA, US, vol. 58, 1989, pages 913-948, XP008008244 ISSN: 0066-4154
  • SHEN Y ET AL: "HERPES SIMPLEX VIRUS 1 (HSV-1) FOR CANCER TREATMENT" CANCER GENE THERAPY, NORWALK, CT, US, vol. 13, 7 April 2006 (2006-04-07), pages 975-992, XP008071389 ISSN: 0929-1903
  • SCHMEISSER FALKO ET AL: "Incorporation of a lambda phage recombination system and EGFP detection to simplify mutagenesis of Herpes simplex virus bacterial artificial chromosomes" BMC BIOTECHNOLOGY, vol. 7, May 2007 (2007-05), page Article No.: 22, XP002448126 ISSN: 1472-6750
  • NAKANO MASAKAZU ET AL: "Production of viral vectors using recombinase-mediated cassette exchange", 20050101; 20050000, vol. 33, no. 8, 1 January 2005 (2005-01-01), page e76, XP002454932,
  • NAKANO MASAKAZU ET AL: "Production of viral vectors using recombinase-mediated cassette exchange", 20050101; 20050000, vol. 33, no. 8, 1 January 2005 (2005-01-01), page E76, XP002454932,
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).